- Pfizer’s (NYSE:PFE) coronavirus vaccine could be distributed to Americans before the end of the year if found to be safe and effective, CEO Albert Bourla said Sunday, source CNBC.
- Bourla said Pfizer and its partner BioNTech (NASDAQ:BNTX) have a 60% chance of knowing the efficacy of its still experimental vaccine by the end of October.
- “Of course that doesn’t mean that it works; that means that we’ll know if it works,” Bourla said. The Phase 3 trials are expected to continue well beyond October, but the company is hoping that early data would present adequate data to assess its effectiveness.
- If the FDA approves the vaccine, the company is prepared to distribute “hundreds of thousands of doses,” said CEO Bourla during an interview on CBS’ “Face the Nation”.
- A day earlier, PFE/BNTX submitted a proposal to the FDA to expand its Phase 3 trials to include more volunteers from diverse population groups.
- Previously: Pfizer to seek FDA emergency use nod for COVID-19 vaccine as early as October (July 28)
- Previously: Pfizer, BioNTech ink deal with U.S. government for 600M doses of COVID-19 vaccine (July 22)